Table 1 Table of subject characteristics.

From: Identification of differences in CD4+ T-cell gene expression between people with asthma and healthy controls

 

N

Asthmatics**

N = 33

Controls

N = 12

p-value

Female (%)

45

11 (33)

6 (50)

0.3

Current smoker (%)

45

3 (9.1)

0 (0)

0.6

Median FeNO (ppb, IQR)

45

24 (18–38)

14 (12–18)

0.008

Positive mannitol challenge (%)

42

17 (57)

3 (25)

0.063

Median PD15 (IQR)*

20

187 (51–258)

554 (383, 584)

0.093

Median FEV1/FVC (IQR)

45

84.0 (80.0–87.8)

87.3 (84.1–89.7)

0.088

Median BMI (IQR)

45

23.9 (21.6–25.8)

21.7 (20.3–23.2)

0.1

HDM SPT age 18

44

19 (59%)

3 (25%)

0.04

Age (years)

45

22.4 (21.8–22.7)

23.0 (22.8–23.1)

0.002

Medication

 None (%)

33

9 (27)

  

 Inhaled corticosteroids (ICS) (%)

9 (27)

  

 Combination Inhalers (contains both LABA and ICS) (%)

5 (15)

  

 SABA only (%)

10 (30)

  
  1. IQR 25th–75th interquartile range, FeNO fractional exhaled nitric oxide, ppb parts per billion, FEV1 forced exhalation volume in 1 s, FVC forced vital capacity, BMI body mass index, HDM house dust mite, SPT skin prick test, PD15 dose of mannitol causing a 15% fall in FEV1, LABA long-acting bronchodilator inhalers, SABA short-acting bronchodilator inhalers.
  2. *PD15 was only calculated for the participants who were positive to the mannitol challenge.
  3. **Mannitol challenge was missing for 2 asthma cases; p value from Fisher’s exact test for categorical and Wilcoxon rank sum test for numerical variables.
Back to article page